Lovenox Injection
Product Images NDC 0075-8016

32 FDA label images from Sanofi-aventis U.s. Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 32 technical images submitted to the FDA as part of the official labeling for Lovenox (NDC 0075-8016). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sanofi-aventis U.s. Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure A (De6fb917 A94a 41ea 9d7d 937d4080ffcd 01)

Figure A (De6fb917 A94a 41ea 9d7d 937d4080ffcd 01)
An instructional illustration showing hands preparing a syringe by attaching a needle to its tip, indicating a step in injection preparation. The image focuses on the assembly process prior to administration, with an arrow highlighting the direction of needle attachment.*
FDA Label Image

Figure B (De6fb917 A94a 41ea 9d7d 937d4080ffcd 02)

Figure B (De6fb917 A94a 41ea 9d7d 937d4080ffcd 02)
An instructional illustration depicting the subcutaneous injection technique for Lovenox (enoxaparin sodium) injection. The image shows a hand holding a syringe at an angle, injecting beneath the skin of the abdomen, with an arrow indicating the direction of injection.*
FDA Label Image

Figure C (De6fb917 A94a 41ea 9d7d 937d4080ffcd 03)

Figure C (De6fb917 A94a 41ea 9d7d 937d4080ffcd 03)
Illustration showing a hand administering a subcutaneous injection with a syringe, indicating injection into the skin at an angle consistent with subcutaneous delivery. A blue arrow points toward the injection site, emphasizing the direction of needle insertion.*
FDA Label Image

Figure D (De6fb917 A94a 41ea 9d7d 937d4080ffcd 04)

Figure D (De6fb917 A94a 41ea 9d7d 937d4080ffcd 04)
An instructional illustration showing a hand holding a prefilled syringe for subcutaneous injection, with an arrow indicating the motion to press or inject. The image implies proper technique for administering a Lovenox (enoxaparin sodium) injection.*
FDA Label Image

Figure E (De6fb917 A94a 41ea 9d7d 937d4080ffcd 05)

Figure E (De6fb917 A94a 41ea 9d7d 937d4080ffcd 05)
An instructional illustration showing a hand pressing down on a device labeled 'BIONATOR.' The image demonstrates how to activate or use the device, indicated by a downward blue arrow above the hand.*
FDA Label Image

Chemical Structure (De6fb917 A94a 41ea 9d7d 937d4080ffcd 06)

Chemical Structure (De6fb917 A94a 41ea 9d7d 937d4080ffcd 06)
Chemical structure diagram of enoxaparin sodium, the active ingredient in Lovenox injection. The diagram shows a repeating polysaccharide chain with various functional groups including carboxylate and hydroxyl groups.*
FDA Label Image

Chemical Structure (De6fb917 A94a 41ea 9d7d 937d4080ffcd 07)

Chemical Structure (De6fb917 A94a 41ea 9d7d 937d4080ffcd 07)
Chemical structure of enoxaparin sodium, the active ingredient in Lovenox injection. The diagram shows a portion of the molecular structure with various chemical bonds and functional groups typical of enoxaparin sodium.*
FDA Label Image

Figure 1 (De6fb917 A94a 41ea 9d7d 937d4080ffcd 08)

Figure 1 (De6fb917 A94a 41ea 9d7d 937d4080ffcd 08)
A forest plot chart depicting relative risk comparisons of unfractionated heparin (UFH) versus enoxaparin sodium (Enox) across various patient subgroups and conditions. It shows risk percentages for UFH and Enox, the reduction in risk, and includes markers indicating relative risk favoring either treatment. The data covers sex, age, infarct location, diabetes status, prior myocardial infarction, fibrinolytic agent type, time to treatment, and PCI in 30 days, with an overall risk comparison at the bottom.*
FDA Label Image

Figure 2 (De6fb917 A94a 41ea 9d7d 937d4080ffcd 09)

Figure 2 (De6fb917 A94a 41ea 9d7d 937d4080ffcd 09)
A Kaplan-Meier hazard distribution function chart comparing time to death or myocardial re-infarction over 30 days for enoxaparin (Lovenox) versus unfractionated heparin (UFH). The main plot shows enoxaparin with lower hazard over time. A smaller inset graph depicts similar data at 1 year, with enoxaparin again showing a lower hazard. Risk numbers at various time points for both treatments are listed below the x-axis.*
FDA Label Image

Image (De6fb917 A94a 41ea 9d7d 937d4080ffcd 10)

Image (De6fb917 A94a 41ea 9d7d 937d4080ffcd 10)
An instructional illustration showing a syringe before and after use. The diagram labels components such as the plunger rod, needle, and needle cap before use, and the plunger rod and protective sleeve after use. The image demonstrates syringe handling steps for injection preparation and disposal.*
FDA Label Image

Figure A (De6fb917 A94a 41ea 9d7d 937d4080ffcd 11)

Figure A (De6fb917 A94a 41ea 9d7d 937d4080ffcd 11)
An instructional diagram showing components included with Lovenox injection at subcutaneous route. The image depicts one Lovenox prefilled syringe, a sharps disposal container, one cotton ball or gauze, one alcohol wipe, and one small adhesive bandage, illustrating standard supplies for administering the injection safely and properly.*
FDA Label Image

Figure B (De6fb917 A94a 41ea 9d7d 937d4080ffcd 12)

Figure B (De6fb917 A94a 41ea 9d7d 937d4080ffcd 12)
An instructional illustration showing hands preparing a prefilled syringe by peeling back the protective covering to expose the needle area, likely for subcutaneous injection of Lovenox (enoxaparin sodium).*
FDA Label Image

Figure C (De6fb917 A94a 41ea 9d7d 937d4080ffcd 13)

Figure C (De6fb917 A94a 41ea 9d7d 937d4080ffcd 13)
Black and white line drawing illustration of a prefilled syringe labeled for Lovenox (enoxaparin sodium) injection. The syringe has a protective cap on the needle end, a body with measurement markings, and a plunger. The expiration date is indicated near the syringe body.*
FDA Label Image

Figure D (De6fb917 A94a 41ea 9d7d 937d4080ffcd 14)

Figure D (De6fb917 A94a 41ea 9d7d 937d4080ffcd 14)
An illustration of a Lovenox prefilled syringe showing the clear liquid medication inside. The syringe includes the plunger, barrel, and needle cover, designed for subcutaneous injection of enoxaparin sodium by Sanofi-Aventis U.S. LLC.*
FDA Label Image

Figure E (De6fb917 A94a 41ea 9d7d 937d4080ffcd 15)

Figure E (De6fb917 A94a 41ea 9d7d 937d4080ffcd 15)
An instructional diagram showing the abdominal area with two shaded rectangular zones on each side of the navel, indicating recommended subcutaneous injection sites. This is relevant for administration of an injectable drug such as Lovenox (enoxaparin sodium).*
FDA Label Image

Figure F (De6fb917 A94a 41ea 9d7d 937d4080ffcd 16)

Figure F (De6fb917 A94a 41ea 9d7d 937d4080ffcd 16)
An instructional illustration showing a hand administering a subcutaneous injection into the abdomen area, near the navel, demonstrating the proper placement for injection of a subcutaneous drug like Lovenox (enoxaparin sodium).*
FDA Label Image

Figure G (De6fb917 A94a 41ea 9d7d 937d4080ffcd 17)

Figure G (De6fb917 A94a 41ea 9d7d 937d4080ffcd 17)
An instructional illustration showing a person removing a protective cap from a syringe. The image includes two hands, one holding the syringe and the other pulling the cap off in the direction indicated by double-headed arrows.*
FDA Label Image

Figure H (De6fb917 A94a 41ea 9d7d 937d4080ffcd 18)

Figure H (De6fb917 A94a 41ea 9d7d 937d4080ffcd 18)
An instructional illustration showing a hand holding a syringe labeled with measurement markings. The image demonstrates the action of setting the dose by pushing down on the plunger, indicated by a downward arrow and the text 'Set your dose.' This image relates to Lovenox (enoxaparin sodium) injection administration.*
FDA Label Image

Figure I (De6fb917 A94a 41ea 9d7d 937d4080ffcd 19)

Figure I (De6fb917 A94a 41ea 9d7d 937d4080ffcd 19)
An instructional illustration showing a hand pinching the abdominal skin to prepare for a subcutaneous injection, consistent with the administration route for Lovenox (enoxaparin sodium) injection.*
FDA Label Image

Figure J (De6fb917 A94a 41ea 9d7d 937d4080ffcd 20)

Figure J (De6fb917 A94a 41ea 9d7d 937d4080ffcd 20)
Instructional illustration showing subcutaneous injection technique, with a hand holding a syringe injecting into the abdominal area at a 90-degree angle. An arrow indicates the direction of injection, demonstrating proper administration method.*
FDA Label Image

Figure K (De6fb917 A94a 41ea 9d7d 937d4080ffcd 21)

Figure K (De6fb917 A94a 41ea 9d7d 937d4080ffcd 21)
An instructional illustration depicts the administration of a subcutaneous injection. It shows one hand pinching the skin while the other hand inserts a syringe at an angle into the lower abdomen, indicating the injection technique for Lovenox (enoxaparin sodium) injection.*
FDA Label Image

Figure L (De6fb917 A94a 41ea 9d7d 937d4080ffcd 22)

Figure L (De6fb917 A94a 41ea 9d7d 937d4080ffcd 22)
An instructional illustration depicting the administration of a subcutaneous injection into the abdominal area. The image shows a hand pinching the skin near the waistline and another hand holding a syringe with the needle pointed toward the pinched skin, with an arrow indicating the direction of injection.*
FDA Label Image

Figure M (De6fb917 A94a 41ea 9d7d 937d4080ffcd 23)

Figure M (De6fb917 A94a 41ea 9d7d 937d4080ffcd 23)
An instructional illustration showing a hand holding a syringe with a label indicating to 'CLICK' as the plunger is pulled back. The syringe also has a protective sleeve positioned over the needle area.*
FDA Label Image

Figure N (De6fb917 A94a 41ea 9d7d 937d4080ffcd 24)

Figure N (De6fb917 A94a 41ea 9d7d 937d4080ffcd 24)
An instructional diagram showing a hand disposing of a used Lovenox syringe with needle cap attached into a labeled sharps disposal container. The image highlights safe disposal of the Lovenox injection syringe and needle cap.*
FDA Label Image

Principal Display Panel (30 mg/0.3 mL Syringe Blister Pack Carton)

Principal Display Panel (30 mg/0.3 mL Syringe Blister Pack Carton)
Packaging label for Lovenox (enoxaparin sodium injection) 30 mg/0.3 mL single-dose syringes with automatic safety device for subcutaneous injection. The label indicates Rx only, manufactured by Sanofi-Aventis U.S. LLC, with a package size of ten 0.3 mL syringes. The label provides storage instructions and usage directions with safety illustrations on the inside panel.*
FDA Label Image

Principal Display Panel (40 mg/0.4 mL Syringe Blister Pack Carton)

Principal Display Panel (40 mg/0.4 mL Syringe Blister Pack Carton)
Packaging label for Lovenox (enoxaparin sodium injection) 40 mg/0.4 mL by Sanofi-Aventis U.S. LLC. The label indicates the product is for subcutaneous injection and contains ten 0.4 mL single-dose syringes with an automatic safety device. The box includes dosage and administration instructions and storage information, highlighting the product is Rx only.*
FDA Label Image

Principal Display Panel (60 mg/0.6 mL Syringe Blister Pack Carton)

Principal Display Panel (60 mg/0.6 mL Syringe Blister Pack Carton)
Packaging label for Lovenox (enoxaparin sodium injection) 60 mg/0.6 mL single-dose syringes with automatic safety device. The label indicates it is for subcutaneous injection and includes storage instructions. The product is labeled as Rx only and manufactured by Sanofi-Aventis U.S. LLC. The package contains ten 0.6 mL syringes and features instructions for syringe use with accompanying illustrations.*
FDA Label Image

Principal Display Panel (80 mg/0.8 mL Syringe Blister Pack Carton)

Principal Display Panel (80 mg/0.8 mL Syringe Blister Pack Carton)
Lovenox 80 mg/0.8 mL (enoxaparin sodium injection) carton for ten single-dose syringes with automatic safety device. The subcutaneous injection packaging shows dosage strength, route, and directions for syringe use. Labeler is Sanofi-Aventis U.S. LLC. Includes storage instructions and manufacturer details.*
FDA Label Image

Principal Display Panel (100 mg/1 mL Syringe Blister Pack Carton)

Principal Display Panel (100 mg/1 mL Syringe Blister Pack Carton)
Lovenox (enoxaparin sodium injection) 100 mg/mL single dose syringes packaging label for subcutaneous injection. The label indicates it is manufactured by Sanofi-Aventis U.S. LLC and contains ten 1 mL syringes with an automatic safety device. Directions for use and storage instructions are also included on the label.*
FDA Label Image

Principal Display Panel (3 mL Vial Carton)

Principal Display Panel (3 mL Vial Carton)
Packaging label for Lovenox 300 mg/3 mL (100 mg/mL) enoxaparin sodium injection, a subcutaneous or intravenous injection. The label indicates Rx only, multiple dose vial, one 3 mL vial per package. It is labeled by Sanofi-Aventis U.S. LLC with storage and administration instructions, and includes a barcode and trademark information.*
FDA Label Image

Principal Display Panel (120 mg/0.8 mL Syringe Blister Pack Carton)

Principal Display Panel (120 mg/0.8 mL Syringe Blister Pack Carton)
Packaging label for Lovenox (enoxaparin sodium injection) 120 mg/0.8 mL, single dose syringes with automatic safety device, for subcutaneous injection. The label indicates the product is Rx only and comes in a package of ten 0.8 mL syringes. Manufactured by Sanofi-Aventis U.S. LLC.*
FDA Label Image

Principal Display Panel (150 mg/1 mL Syringe Blister Pack Carton)

Principal Display Panel (150 mg/1 mL Syringe Blister Pack Carton)
Packaging label for Lovenox 150 mg/mL injection containing enoxaparin sodium. The label indicates single-dose syringes with automatic safety devices for subcutaneous injection. The box contains ten 1 mL syringes. Labeler is Sanofi-Aventis U.S. LLC. Includes dosage instructions, warnings, and storage information with detailed illustration for syringe use and safety system activation.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.